$670 Million Settlement vs. Bellwether Victory: Two Very Different Paths In The Infant Formula Nec Litigation
In August 2026, Abbott Laboratories agreed to pay $670 million to resolve roughly 2,000 legal claims. The lawsuits alleged that the company’s specialized infant formulas contributed to necrotizing enterocolitis (NEC), a severe, often fatal intestinal disease that primarily affects premature infants1. This massive settlement also brought an end to Abbott’s appeal of a $495 million jury verdict awarded to the family of Margo Gill, after the Missouri Court of Appeals upheld the decision earlier in May 2026.1213
Only eleven days later, a federal bellwether trial involving rival manufacturer Mead Johnson delivered a starkly different verdict.1415 On August 31, 2026, a federal jury in the Northern District of Illinois cleared Mead Johnson of all liability, concluding that its product, Enfamil Premature formula, did not cause the plaintiff’s infant to develop NEC.1617
Together, these conflicting turns highlight why mass-tort litigation rarely proceeds along a predictable path. A major payout by one manufacturer does not inherently mean liability for another, just as a complete defense win in a bellwether trial does not immediately resolve a multidistrict litigation (MDL).18
NEC is a devastating diagnosis for families. The condition causes severe inflammation that destroys the lining of the delicate infant intestine, often leading to emergency surgery, long-term disability, or death.19
The legal battle has expanded into both state and federal court dockets. More than 825 lawsuits against both Abbott and Mead Johnson have been consolidated into a federal MDL in the Northern District of Illinois.2021 Meanwhile, thousands of additional claims remain pending in state courts across Illinois, Missouri, and Pennsylvania. Following the August settlement, Abbott disclosed in regulatory filings that approximately 1,700 lawsuits representing about 12,700 infant claims remain active on its specific docket.22
Inside Abbott’s $670 Million Settlement
On August 20, 2026, Abbott announced its $670 million agreement covering around 2,000 infant claims. Crucially, the deal put an end to the protracted litigation over the $495 million verdict awarded to Margo Gill, an Illinois mother whose premature daughter suffered severe, permanent injuries after being fed Abbott’s Similac formula.2324
That earlier verdict was particularly significant. Jurors found Abbott liable for failing to warn about product risks and levied $400 million in punitive damages alongside $95 million in compensatory damages2. After the Missouri Court of Appeals affirmed the judgment in May 2026, Abbott faced a steep uphill appellate battle.
Despite settling, Abbott has not admitted any wrongdoing or liability1. The company continues to maintain that its preterm formulas are safe, medically vital, and essential for premature infants when mother’s milk or donor milk is unavailable.
Financial math also drove the decision: Abbott noted that post-judgment interest on the $495 million award had pushed the total amount owed in the Gill case alone to roughly $600 million. Resolving thousands of additional claims for $670 million offered a far more logical resolution than continuing to fight a single ballooning judgment.
Mead Johnson’s Bellwether Defense Victory
Just 11 days after Abbott’s announcement, the litigation narrative took a sharp turn. On August 31, 2026, a federal jury in Chicago returned a full defense verdict in favor of Mead Johnson in the case of Inman v. Mead Johnson. The lawsuit was brought by Alexis Inman on behalf of her son, Daniel Windley, who was born prematurely at 29 weeks and tragically died after contracting NEC.
The plaintiff argued that Mead Johnson failed to adequately warn medical staff about the potential risks associated with Enfamil Premature formula1,3. However, the jury disagreed, concluding that the plaintiff failed to establish that Enfamil was the actual cause of the child’s illness.
This victory was a landmark development for Mead Johnson, as the Inman case represented the very first federal bellwether trial in the consolidated MDL to reach a jury verdict against the company.
Comparing the Two Litigation Outcomes
The litigation outcomes involving Abbott Laboratories and Mead Johnson illustrate two markedly different approaches to resolving product-liability claims. Abbott Laboratories ultimately agreed to a $670 million settlement resolving approximately 2,000 individual claims, following an affirmed $495 million verdict, while continuing to deny liability and maintain the safety of its product. By contrast, Mead Johnson secured a defense verdict in the federal bellwether trial involving Inman, after an Illinois appellate court had reversed an earlier adverse verdict. Mead Johnson likewise rejected the plaintiffs’ causation theories, relying on medical evidence to support its position that the product did not cause the alleged injuries. Thus, while Abbott’s litigation strategy culminated in a broad global settlement that brought a substantial number of claims to resolution, Mead Johnson has continued to pursue a more case-specific defense strategy, including vigorously defending individual cases at trial. Collectively, the contrasting outcomes demonstrate how appellate rulings, the strength of causation evidence, and the risks associated with individual bellwether trials can materially influence the ultimate litigation strategy and resolution of mass product-liability claims.
Causation Remains the Central Battleground
Because premature infants are inherently at high risk for NEC due to underdeveloped digestive and immune systems, establishing specific causation is notoriously difficult1. While plaintiffs point to clinical studies linking cow’s-milk products to higher NEC rates, defense attorneys argue that lack of breastmilk rather than formula exposure, is the true variable, relying on medical literature and clinical trial data.
The Inman verdict demonstrated that when causation evidence is contested, juries are entirely willing to rule in favor of formula manufacturers, even amidst a sea of adverse publicity.
The conflicting developments of August 2026 will not bring the NEC litigation to an immediate conclusion. Instead, they will force both sides to scrutinize their remaining case dockets far more granularly.